InterVene, Inc. raised $13M in a Series A led by Treo Ventures and RiverVest Venture Partners to advance the Recana™ system through US market clearance.
InterVene, Inc. raised $13M in a Series A led by Treo Ventures and RiverVest Venture Partners to advance the Recana™ system through US market clearance.
10/07/24, 12:17 PM
Location
redwood cityMoney raised
$13 million
Industry
healthcare
Round Type
series a
Investors
River Vest Venture Partners, Treo Ventures
InterVene, Inc. announced the closing of its $13M Series A financing round co-led by Treo Ventures and RiverVest Venture Partners. The proceeds will fund the final development of its Recana catheter system and support preparation for initial commercialization.
Company Info
Location
redwood city, california, united states
Additional Info
InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that.